Wave Life Sciences Ltd. or Galapagos NV: Who Invests More in Innovation?

Biotech Giants' R&D Race: Galapagos vs. Wave Life Sciences

__timestampGalapagos NVWave Life Sciences Ltd.
Wednesday, January 1, 20141111100002395000
Thursday, January 1, 20151297140009057000
Friday, January 1, 201613957400040818000
Sunday, January 1, 201721850200079309000
Monday, January 1, 2018322876000134428000
Tuesday, January 1, 2019427320000175431000
Wednesday, January 1, 2020523667000130944000
Friday, January 1, 2021491707000121875000
Saturday, January 1, 2022515083000115856000
Sunday, January 1, 2023241294000130009000
Loading chart...

Unlocking the unknown

Investing in Innovation: A Tale of Two Biotech Giants

In the competitive world of biotechnology, innovation is the lifeblood of success. Over the past decade, Galapagos NV and Wave Life Sciences Ltd. have been at the forefront of this race, each investing heavily in research and development (R&D) to push the boundaries of science. From 2014 to 2023, Galapagos NV consistently outpaced Wave Life Sciences in R&D spending, with an average annual investment nearly three times higher. Notably, in 2020, Galapagos NV peaked with an R&D expenditure that was approximately 300% more than Wave Life Sciences. However, Wave Life Sciences has shown a steady increase in its R&D budget, reflecting its commitment to innovation. As these companies continue to invest in groundbreaking research, the biotech industry watches closely, anticipating the next big breakthrough that could redefine healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025